During the past decade, Centre Hospitalier de Blois conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 4 clinical trials were completed, i.e. on average, 12.1% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 4 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre Hospitalier de Blois" #1 sponsor was "Federation Francophone de Cancerologie Digestive" with 9 trials, followed by "Intergroupe Francophone du Myelome" with 6 trials sponsored, "UNICANCER" with 6 trials sponsored, "The Lymphoma Academic Research Organisation" with 5 trials sponsored and "Celgene" with 5 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Hospitalier de Blois" #1 collaborator was "GERCOR - Multidisciplinary Oncology Cooperative Group" with 3 trials as a collaborator, "Janssen-Cilag Ltd." with 3 trials as a collaborator, "ARCAGY/ GINECO GROUP" with 2 trials as a collaborator, "AbbVie" with 2 trials as a collaborator and "AstraZeneca" with 2 trials as a collaborator. Other collaborators include 22 different institutions and companies that were collaborators in the rest 30 trials.

According to Clinical.Site data, the most researched conditions in "Centre Hospitalier de Blois" are "Multiple Myeloma" (5 trials), "Colorectal Cancer" (4 trials), "Crohn Disease" (3 trials), "Myeloma" (3 trials) and "Breast Cancer" (2 trials). Many other conditions were trialed in "Centre Hospitalier de Blois" in a lesser frequency.

Most popular intervention types in "Centre Hospitalier de Blois" are "Drug" (44 trials), "Other" (12 trials), "Procedure" (8 trials), "Radiation" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "fluorouracil" (4 trials), "Lenalidomide" (3 trials), "Ozanimod" (3 trials), "Placebo" (3 trials) and "Rituximab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Centre Hospitalier de Blois" are 55 trials for "All" genders, 9 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Centre Hospitalier de Blois". undefined are not yet recruiting, 9 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 40 completed trials in Centre Hospitalier de Blois, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Centre Hospitalier de Blois, 0 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 31 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 9 trials that are defined as “Not Applicable".